Anzeige
Mehr »
Donnerstag, 18.09.2025 - Börsentäglich über 12.000 News
Die Ethereum-Vorreiter: Wie Republic Technologies die Infrastruktur der Zukunft aufbaut
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
1.092 Leser
Artikel bewerten:
(2)

EndoQuest Robotics Partners with OMNIVISION to Equip Flexible Robotic System with Industry-leading Image Sensor

Novel flexible robotic system to offer best-in-class endoscopic visualization

HOUSTON, Jan. 5, 2024 /PRNewswire/ -- EndoQuest Robotics, Inc., a privately-held medical device company and pioneering leader in the development of innovative endoluminal robotic technologies, and OMNIVISION, a leading global developer of semiconductor solutions, including advanced digital imaging, and touch display technology, announced today a partnership to integrate OMNIVISION's OCHFA CameraCubeChip® into EndoQuest's Flexible Robotic System.

Enabling Flexible Robotic Surgery

"We are excited to be able to incorporate OMNIVISION's market-leading sensor technology into the visualization component of our first of its kind platform," said Kurt Azarbarzin, CEO of EndoQuest Robotics. "We recognize that advanced imaging is essential to enhancing physician capabilities, especially inside the lumen of the gastrointestinal (GI) tract. OMNIVISION's newest technology is ideal for our Flexible Robotic System."

"We are pleased to integrate our OCHFA CameraCubeChip® into the EndoQuest Robotics platform," said Tehzeeb Gunja, OMNIVISION's Director of Medical Marketing. "The OCHFA CameraCubeChip® is a high-performance visualization solution built with OMNIVISION's PureCel®Plus-S pixel technology, with a small 1.008-micron (µm) pixel size, in a 1/8-inch optical format; it features 720x720 resolution at 30 frames per second. The PureCel®Plus-S technology enables high full-well capacity, zero blooming and lower power consumption for crisp, clear life-like images. The OCHFA CameraCubeChip® comes in a compact 1.075 x 1.075-millimeter (mm) size, with a 5mm to 50mm focus range and 120-degree diagonal field-of-view that is ideal for GI and other endoluminal procedures. It is a medical-grade, trusted component that undergoes comprehensive certification, qualification and testing, taking patient care and surgical visualization to the next level."

EndoQuest Robotics is focused on addressing the unmet needs in GI and other endoluminal surgeries by developing an innovative robotic system that offers precision, flexibility and improved patient outcomes. The company's proprietary technology is designed to navigate and perform procedures within the body's natural orifices, allowing for the least invasive interventions and enhancing the capabilities of healthcare professionals. Since EndoQuest Robotics was founded, the company has collaborated extensively and will continue to do so with healthcare providers, researchers, and industry partners to advance the adoption of its revolutionary flexible endoluminal robotic system, ultimately improving patient outcomes and redefining a new standard of care in minimally invasive surgery.

About OMNIVISION
OMNIVISION is a global fabless semiconductor organization that develops advanced digital imaging, analog, and touch & display solutions for multiple applications and industries, including mobile phones; security and surveillance; automotive; computing; medical; and IoT / emerging applications. Its award-winning innovative technologies enable a smoother human/machine interface in many of today's commercial devices. Find out more at www.ovt.com.

About EndoQuest Robotics
EndoQuest Robotics is a leading innovator in the development of transformative endoluminal robotic technologies. The company is dedicated to revolutionizing minimally invasive procedures by creating cutting-edge endoluminal interventions tailored for therapeutic endoscopists and surgeons to perform upper and lower gastrointestinal surgery less-invasively with a focus on enhancing precision, flexibility and patient outcomes. For additional information, visit the company's website at www.endoquestrobotics.com.

EndoQuest's Flexible Robotic System is under development, has not been cleared by the FDA and is not for commercial sale in the United?States.

For media inquiries or further information about EndoQuest Robotics and its groundbreaking advancements in flexible endoluminal robotics, please contact:

Company Contacts:


Chris Klecher
949.310.8271
chris.klecher@endoquestrobotics.com


OMNIVISION Media Contact:
Sandy Fewkes
Kiterocket
+1 408.529.9685
sfewkes@kiterocket.com

Gary Tegan
612.889.9490
gary.tegan@endoquestrobotics.com


OMNIVISION Company Contact:
DeAnn Liu
OMNIVISION
+1 408.916.2536
PR@ovt.com

OMNIVISION

Logo - https://mma.prnewswire.com/media/2291189/EndoQuest_Robotics_Logo.jpg
Logo - https://mma.prnewswire.com/media/2311601/Omnivision_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/endoquest-robotics-partners-with-omnivision-to-equip-flexible-robotic-system-with-industry-leading-image-sensor-302026860.html

© 2024 PR Newswire
Epische Goldpreisrallye
Der Goldpreis hat ein neues Rekordhoch überschritten. Die Marke von 3.500 US-Dollar ist gefallen, und selbst 4.000 US-Dollar erscheinen nur noch als Zwischenziel.

Die Rallye wird von mehreren Faktoren gleichzeitig getrieben:
  • · massive Käufe durch Noten- und Zentralbanken
  • · Kapitalflucht in sichere Häfen
  • · hohe Nachfrage nach physisch besicherten Gold-ETFs
  • · geopolitische Unsicherheit und Inflationssorgen

Die Aktienkurse vieler Goldproduzenten und Explorer sind in den vergangenen Wochen regelrecht explodiert.

Doch es gibt noch Titel, die Nachholpotenzial besitzen. In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Goldaktien jetzt besonders aussichtsreich sind und warum der Aufwärtstrend noch lange nicht vorbei sein dürfte.

Laden Sie jetzt den Spezialreport kostenlos herunter und profitieren Sie von der historischen Gold-Hausse.

Dieses Angebot gilt nur für kurze Zeit – also nicht zögern, jetzt sichern!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.